Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Tissue microarray validation

Author: Valerie Speirs

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

For well over a century, pathologists have used formalin-fixed paraffin-embedded tissues for microscopic examination and subsequent diagnosis of human disease. This type of approach is usually limited to the analysis and/or detection of one or two specific features on a single slide from an individual section. The recent development of tissue microarrays (see Additional information) involves core needle 'biopsies' of multiple pre-existing paraffin-embedded tissue blocks and re-embedding them in the form of an arrayed master block. Thus, tissue from an entire cohort of specimens can be represented in a single block and processed under identical conditions. This study evaluated the potential of using tissue microarrays of archival formalin-fixed paraffin-embedded breast tumours to detect expression of three common antigens in breast cancer: estrogen receptor (ER), progesterone receptor (PR) and Her2/neu. …
Literature
1.
go back to reference Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest . 2000, 80: 1943-1949.CrossRefPubMed Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest . 2000, 80: 1943-1949.CrossRefPubMed
Metadata
Title
Tissue microarray validation
Author
Valerie Speirs
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68443

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine